One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Plasma Fractionation Market

血漿分画市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Plasma Fractionation Market by Product (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors, and Others), Application (Neurology, Immunology, Hematology, Critical Care, Rheumatology, Pulmonology, and Others), End Users (Hospitals & Clinics, Clinical Research Laboratories, and Academic Institutes), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2019-2027


Product Code : RDHC00114222
Survey : Research Dive
Publish On : July, 2021
Number of Pages : 165
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5700 / Question Form
5 User USD8700 / Question Form
Enterprise User USD10700 / Question Form
Kedrion S.P.A, Sanquin, Octapharma, Japan Blood Products, Bio Products Laboratory, China Biologics Products Holdings, Biotest AG, CSL Behring, Octapharma AG, and Grifols.

[Report Description]

According to Research Dive analysis, the global plasma fractionation market is estimated to generate a revenue of $45,805.8 million by 2027, increasing from $ 25,403.4 million in 2019, at a healthy CAGR of 7.0%.

Impact Analysis of COVID-19 on the Global Plasma Fractionation Market:
During the COVID-19 pandemic, plasma therapy emerged as a hope for the patients and this has accelerated the plasma fractionation market growth. The convalescent plasma derived from recovered coronavirus patients is used for the treatment of infected patients. Although, the pandemic resulted in growth of the plasma fractionation market, it has also had a negative impact on the market. The pandemic resulted in reduced demand for the plasma therapeutics due to delayed surgeries and treatment of autoimmune disorders as the number of donors decreased and thus the supply of blood.
Global Plasma Fractionation Market Analysis:
Rising demand for immunoglobulins in application centers such as neurological, immunology, pulmonary, hematological, and other therapeutics will accelerate the plasma fractionation market growth. For instance, as per the news published in Pharmacy Time, on April 29, 2021, plasma therapy and intravenously-injected immunoglobulin treatment have been studied to be an effective therapeutic option to treat COVID-19 infection.
Also, increasing autoimmune diseases in geriatric population is anticipated to flourish the growth of the plasma fractionation market globally. Furthermore, the establishment of plasma collection centers at various places across the world for plasma donation and processing by healthcare communities and government have also increased the market revenue of plasma fractionation market.
However, the high cost of plasma therapy restrains the market from growth. Also, the increasing use of alternatives such as fibrinogen concentration for treating chronic diseases like type 1 diabetes has also obstructed the plasma fractionation market growth. Moreover, the restricted medical reimbursement policies for plasma therapy further impedes the growth of the market.
Various companies are investing in research and developmental activities in plasma therapy. The coronavirus pandemic has opened various opportunities for biotech and biopharma companies to work in research and development to discover and innovate plasma therapies. Many companies have decided to go for collaborations to study the effectiveness of plasma therapy on COVID patients. Furthermore, unhealthy lifestyle such as consumption of alcohol and tobacco, fast food and more increases the risk of inflammatory disorders in people, which consequently increases the opportunities for the plasma fractionation market growth.
Based on product, the plasma fractionation market is mainly classified into sub-segments like immunoglobulin, albumin, coagulation factors, protease inhibitors, and others.
The immunoglobulin sub-segment shall have the fastest market growth and it is anticipated to generate a revenue of $22,439.3 million by 2027.
Based on application type, the plasma fractionation market is divided into sub-segments such as neurology, immunology, hematology, critical care, rheumatology, pulmonology, and others. The neurology sub-segment garnered $16862.3 million in 2019 and is projected to grow exponentially by 2027.
Based on end user, the global market is divided into hospitals & clinics, clinical research laboratories, and academic institutes. The hospitals & clinics sub-segment is predicted to be growing significantly, and it is expected to cross $ 41162.7 million by 2027.
Based on geographical scope, the market was investigated across North America, Europe, Asia-Pacific, and LAMEA. The Asia-Pacific plasma fractionation market is anticipated to rise at a growth rate of 8.3% by 2027 from the revenue generated in 2019.
The companies involved in the global plasma fractionation market are Kedrion S.P.A, Sanquin, Octapharma, Japan Blood Products, Bio Products Laboratory, China Biologics Products Holdings, Biotest AG, CSL Behring, Octapharma AG, and Grifols.

CHAPTER 1:RESEARCH METHODOLOGY

1.1.Desk research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters

1.4.1. Assumptions
1.4.2. Forecast parameters

CHAPTER 2:EXECUTIVE SUMMARY

2.1.360° summary
2.2.Product
2.3.Application
2.4.End-Users

CHAPTER 3:MARKET OVERVIEW

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1 Top winning strategies, by year, 2020-2027*
3.2.2.2 Top winning strategies, by development, 2020-2027*(%)
3.2.2.3 Top winning strategies, by company, 2020-2027*

3.3.Porters five forces analysis
3.4.Market dynamics
3.5.Technology landscape
3.6.Regulatory landscape
3.7.Patent landscape
3.8.Market value chain analysis
3.9.Strategic overview
3.10.Impact of key regulations

CHAPTER 4:IMPACT OF COVID-19 ON PLASMA FRACTIONATION MARKET

4.1.Introduction

4.2.COVID-19 health assessment
4.3.Impact of COVID-19 on global economy
4.4.Impact of COVID-19 on plasma fractionation market

4.4.1. Social impact
4.4.2. Technological impact
4.4.3. Investment scenario

4.5.Plasma Fractionation market size and forecast, by region, 2020-2027

CHAPTER 5:PLASMA FRACTIONATION MARKET BY PRODUCT

5.1.OVERVIEW

5.1.1. Market size and forecast, by product

5.2. IMMUNOGLOBULIN

5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis, by country

5.3. ALBUMIN

5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis, by country

5.4. COAGULATION FACTORS

5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis, by country

5.5. PROTEASE INHIBITORS

5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis, by country

5.6. OTHERS

5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis, by country

CHAPTER 6:PLASMA FRACTIONATION MARKET BY APPLICATION

6.1.OVERVIEW

6.1.1. Market size and forecast, by application

6.2. NEUROLOGY

6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis, by country

6.3. IMMUNOLOGY

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis, by country

6.4. HEMATOLOGY

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis, by country

6.5. CRITICAL CARE

6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis, by country

6.6. RHEUMATOLOGY

6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis, by country

6.7. PULMONOLOGY

6.7.1. Key market trends, growth factors and opportunities
6.7.2. Market size and forecast, by region
6.7.3. Market share analysis, by country

6.8. OTHERS

6.8.1. Key market trends, growth factors and opportunities
6.8.2. Market size and forecast, by region
6.8.3. Market share analysis, by country

CHAPTER 7:PLASMA FRACTIONATION MARKET BY END-USERS

7.1.OVERVIEW

7.1.1. Market size and forecast, by end-users

7.2. HOSPITALS AND CLINICS

7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis, by country

7.3. CLINICAL RESEARCH LABORATORIES

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region
7.3.3. Market share analysis, by country
7.4. ACADEMIC INSTITUTES

7.4.1. Key market trends, growth factors and opportunities

7.4.2.Market size and forecast, by region
7.4.3.Market share analysis, by country

CHAPTER 8: PLASMA FRACTIONATION MARKET BY REGION

8.1. OVERVIEW

8.1.1.Market size and forecast, by region

8.2. NORTH AMERICA

8.2.1.Key market trends and opportunities
8.2.2.Market size and forecast, by product
8.2.3.Market size and forecast, by application
8.2.4.Market size and forecast, by end-users
8.2.5.Market size and forecast, by Country

8.2.6.U.S.

8.2.6.1.Key market trends and opportunities
8.2.6.2.Market size and forecast, by product
8.2.6.3.Market size and forecast, by application
8.2.6.4.Market size and forecast, by end-users

8.2.7. Canada

8.2.7.1.Key market trends and opportunities
8.2.7.2.Market size and forecast, by product
8.2.7.3.Market size and forecast, by application
8.2.7.4.Market size and forecast, by end-users

8.2.8. Mexico

8.2.8.1.Key market trends and opportunities
8.2.8.2.Market size and forecast, by product
8.2.8.3.Market size and forecast, by application
8.2.8.4.Market size and forecast, by end-users

8.3. EUROPE

8.3.1.Key market trends and opportunities
8.3.2.Market size and forecast, by product
8.3.3.Market size and forecast, by application
8.3.4.Market size and forecast, by end-users
8.3.5.Market size and forecast, by Country

8.3.6.Germany

8.3.6.1.Key market trends and opportunities
8.3.6.2.Market size and forecast, by product
8.3.6.3.Market size and forecast, by application
8.3.6.4.Market size and forecast, by end-users

8.3.7. UK

8.3.7.1.Key market trends and opportunities

8.3.7.2.Market size and forecast, by product
8.3.7.3.Market size and forecast, by application
8.3.7.4.Market size and forecast, by end-users

8.3.8. France

8.3.8.1.Key market trends and opportunities
8.3.8.2.Market size and forecast, by product
8.3.8.3.Market size and forecast, by application
8.3.8.4.Market size and forecast, by end-users

8.3.9. Spain

8.3.9.1.Key market trends and opportunities
8.3.9.2.Market size and forecast, by product
8.3.9.3.Market size and forecast, by application
8.3.9.4.Market size and forecast, by end-users

8.3.10. Italy

8.3.10.1.Key market trends and opportunities
8.3.10.2.Market size and forecast, by product
8.3.10.3.Market size and forecast, by application
8.3.10.4.Market size and forecast, by end-users

8.3.11. Rest of Europe

8.3.11.1.Key market trends and opportunities
8.3.11.2.Market size and forecast, by product
8.3.11.3.Market size and forecast, by application
8.3.11.4.Market size and forecast, by end-users

8.4. ASIA-PACIFIC

8.4.1.Key market trends and opportunities
8.4.2.Market size and forecast, by product
8.4.3.Market size and forecast, by application
8.4.4.Market size and forecast, by end-users
8.4.5.Market size and forecast, by Country

8.4.6.China

8.4.6.1.Key market trends and opportunities
8.4.6.2.Market size and forecast, by product
8.4.6.3.Market size and forecast, by application
8.4.6.4.Market size and forecast, by end-users

8.4.7. Japan

8.4.7.1.Key market trends and opportunities
8.4.7.2.Market size and forecast, by product
8.4.7.3.Market size and forecast, by application
8.4.7.4.Market size and forecast, by end-users

8.4.8. India

8.4.8.1.Key market trends and opportunities
8.4.8.2.Market size and forecast, by product
8.4.8.3.Market size and forecast, by application
8.4.8.4.Market size and forecast, by end-users

8.4.9. South Korea

8.4.9.1.Key market trends and opportunities
8.4.9.2.Market size and forecast, by product
8.4.9.3.Market size and forecast, by application
8.4.9.4.Market size and forecast, by end-users

8.4.10. Australia

8.4.10.1.Key market trends and opportunities
8.4.10.2.Market size and forecast, by product
8.4.10.3.Market size and forecast, by application
8.4.10.4.Market size and forecast, by end-users

8.4.11. Rest of Asia-Pacific

8.4.11.1.Key market trends and opportunities
8.4.11.2.Market size and forecast, by product
8.4.11.3.Market size and forecast, by application
8.4.11.4.Market size and forecast, by end-users

8.5. LAMEA

8.5.1.Key market trends and opportunities
8.5.2.Market size and forecast, by product
8.5.3.Market size and forecast, by application
8.5.4.Market size and forecast, by end-users
8.5.5.Market size and forecast, by Country

8.5.6.Latin America

8.5.6.1.Key market trends and opportunities
8.5.6.2.Market size and forecast, by product
8.5.6.3.Market size and forecast, by application
8.5.6.4.Market size and forecast, by end-users

8.5.7. Middle East

8.5.7.1.Key market trends and opportunities
8.5.7.2.Market size and forecast, by product
8.5.7.3.Market size and forecast, by application
8.5.7.4.Market size and forecast, by end-users

8.5.8. Africa

8.5.8.1.Key market trends and opportunities
8.5.8.2.Market size and forecast, by product
8.5.8.3.Market size and forecast, by application
8.5.8.4.Market size and forecast, by end-users

CHAPTER 9: COMPANY PROFILES

9.1. KEDRION S.P.A

9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. R&D expenditure
9.1.7. Business performance
9.1.8. Key strategic moves and developments

9.2. SANQUIN

9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. R&D expenditure
9.2.7. Business performance
9.2.8. Key strategic moves and developments

9.3. OCTAPHARMA

9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. R&D expenditure
9.3.7. Business performance
9.3.8. Key strategic moves and developments

9.4. JAPAN BLOOD PRODUCTS

9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. R&D expenditure
9.4.7. Business performance
9.4.8. Key strategic moves and developments

9.5. BIO PRODUCTS LABORATORY

9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. R&D expenditure
9.5.7. Business performance
9.5.8. Key strategic moves and developments

9.6. CHINA BIOLOGICS PRODUCTS HOLDINGS

9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. R&D expenditure
9.6.7. Business performance
9.6.8. Key strategic moves and developments

9.7. BIOTEST AG

9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. R&D expenditure
9.7.7. Business performance
9.7.8. Key strategic moves and developments

9.8. CSL BEHRING

9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. R&D expenditure
9.8.7. Business performance
9.8.8. Key strategic moves and developments

9.9. OCTAPHARMA AG

9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. R&D expenditure
9.9.7. Business performance
9.9.8. Key strategic moves and developments

9.10. GRIFOLS

9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. R&D expenditure
9.10.7. Business performance
9.10.8. Key strategic moves and developments

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+